10-Q quarterly report · filed Nov 3, 2026

Pfizer Inc (PFE) Q3 2026 10-Q Quarterly Report

Short answer

Pfizer Inc (PFE) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 27, 2026. Quarterly revenue was $16.6B (down 0.4% year over year) with net income of $3.2B.

Q3 2026 key financials · XBRL

Revenue
$16.6B
−0.4% YoY · +10.3% QoQ
Net income
$3.2B
−8.5% YoY · +1412.1% QoQ
EPS (diluted)
$0.56
−9.7% YoY · +1500.0% QoQ

Source: XBRL data from the Pfizer Inc (PFE) Q3 2026 10-Q on SEC EDGAR. USD.

Pfizer Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $16.6B, down $71M YoY from $16.7B, operationally down $57M
  • Q3 cost-of-sales margin 24.3% vs 25.0% YoY, pretax income $3.4B vs $3.3B
  • Best product: Padcev revenue $720M, up 55% operationally; worst: Paxlovid $449M, down 63%
  • Nine-month operating cash flow $8.825B vs $6.356B; no share repurchases, $1.875B ViiV proceeds
  • Headwinds: 2026 exclusivity expiries expected to reduce revenue by approximately $1.1B, with pricing and regulatory pressures continuing

Risk Factors

  • Patent exclusivity expirations: 2026 revenue impact expected at approximately $1.1 billion
  • IRA pricing pressure: Eliquis Medicare maximum fair price effective January 1, 2026
  • 340B compliance exposure: HHS pilot program for Eliquis, Ibrance and Xtandi expected January 2027, subject to litigation
  • Tariff risk: Section 232 duties up to 100%, with Pfizer’s applicable rate zero until January 20, 2029
  • Product performance risk: Prevnar revenue down 10% operationally in the quarter amid lower vaccination rates and U.S. adult share erosion

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Pfizer Inc quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.